# Serological Science for COVID-19 SeroNet

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2020 · $5,554,144

## Abstract

In light of the emergence of the novel coronavirus, SARS-CoV-2, and the urgent need to mitigate the pathogen’s spread. There is a crucial need for accurate laboratory-based methods for initial diagnosis, asymptomatic carriage and overall public health understanding of the extent of this disease. The current lack of validated and widely available standardized tests, procedures and reagents for assessment of SARS-CoV-2-specific antibody responses is a critical gap in the rapid response to the SARS-CoV-2 pandemic. a major goal and focus of SeroNet is determining the molecular and cellular components of the immune response to SARS-CoV-2 to understand the innate, humoral and adaptive response, as well as to understand barriers to access

## Key facts

- **NIH application ID:** 10281734
- **Project number:** 75N91019D00024-0-759102000003-43
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** LEONARD FREEDMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $5,554,144
- **Award type:** —
- **Project period:** 2020-08-31 → 2021-08-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10281734

## Citation

> US National Institutes of Health, RePORTER application 10281734, Serological Science for COVID-19 SeroNet (75N91019D00024-0-759102000003-43). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10281734. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*